Uncategorized
Ocular Therapeutix to evaluate sustained-release travoprost for glaucoma, ocular hypertension
Ocular Therapeutix has begun enrolling the first subjects in a phase 2b clinical trial to evaluate the safety and efficacy of sustained-release travoprost, according to a press release.Sustained-release travoprost (OTX-TP) is being evaluated for the reduction of elevated IOP in patients with open-angle glaucoma and ocular hypertension.